Literature DB >> 20334922

Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood.

Andreas Barratt-Due1, Ebbe Billmann Thorgersen, Julie K Lindstad, Anne Pharo, Ole-Lars Brekke, Dorte Christiansen, John D Lambris, Tom Eirik Mollnes.   

Abstract

Inhibition of the inappropriate and excessive inflammatory response has been a main issue in sepsis-related research. Historically, TNF-alpha and IL-1 beta have been postulated as key mediators in sepsis, but selective inhibition of these cytokines has failed in clinical trials. Recently it was found that inhibition of upstream recognition by complement and CD14 could efficiently reduce Escherichia coli (E. coli)-induced inflammation. An ex vivo model with lepirudin-anticoagulated human whole blood was used to explore the significance of selective inhibition of TNF-alpha and IL-1 beta in E. coli-induced inflammation. The effect of TNF-alpha, IL-1 beta, complement and CD14 on the inflammatory response was assessed by adding highly specific neutralizing agents to these mediators. Proinflammatory cytokines, expression of CD11b and oxidative burst were measured. The controls included relevant isotype-matched immunoglobulins and peptides. Selective inhibition of TNF-alpha or IL-1 beta had no impact on E. coli-induced release of proinflammatory cytokines, CD11b-upregulation or oxidative burst. In contrast, the combined inhibition of complement and CD14 virtually abolished these responses. These data suggest that both TNF-alpha and IL-1 beta are downstream mediators and as single mediators play a limited role within the complex inflammatory reactions induced by E. coli. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334922     DOI: 10.1016/j.molimm.2010.02.026

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans.

Authors:  Andreas Barratt-Due; Ebbe Billmann Thorgersen; Julie Katrine Lindstad; Anne Pharo; Olga Lissina; John D Lambris; Miles A Nunn; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

2.  Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice.

Authors:  Markus Huber-Lang; Andreas Barratt-Due; Søren E Pischke; Øystein Sandanger; Per H Nilsson; Miles A Nunn; Stephanie Denk; Wilhelm Gaus; Terje Espevik; Tom E Mollnes
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

3.  Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation.

Authors:  Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2013-09-23       Impact factor: 5.422

4.  Gene dosage-dependent negative regulatory role of β-arrestin-2 in polymicrobial infection-induced inflammation.

Authors:  Deepika Sharma; Ankit Malik; Eunhee Lee; Robert A Britton; Narayanan Parameswaran
Journal:  Infect Immun       Date:  2013-06-10       Impact factor: 3.441

5.  An ADAM10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis.

Authors:  Lili Cui; Yan Gao; Yuliu Xie; Yan Wang; Yujie Cai; Xin Shao; Xiaotang Ma; You Li; Guoda Ma; Gen Liu; Wanwen Cheng; Yu Liu; Tingting Liu; Qunwen Pan; Hua Tao; Zhou Liu; Bin Zhao; Yiming Shao; Keshen Li
Journal:  Crit Care       Date:  2015-03-05       Impact factor: 9.097

6.  Genetic association between cluster of differentiation 86 variations and sepsis risk: A case-control study.

Authors:  Xiaofang Zou; Jingning Cai; Bin Li; Shijian Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.